Jessica Hergert

Articles

New Targets May Improve the Treatment of Rare Skin Cancer

June 16, 2021

While merkel cell carcinoma (MCC) tends to have poor prognoses and limited treatment options, promising response rates with checkpoint inhibitors may pave the way for better treatment for the rare skin cancer.

Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer

June 11, 2021

While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.